From plasmids to mRNA, comprehensive nanopore QC tests for biomanufacturing

Abstract Oxford Nanopore Technologies Q-Line devices are uniquely placed to replace legacy testing equipment in biomanufacturing. In this demo we will follow the QC process for both a plasmid and an mRNA sample using the Q-Line GridION: from the simple sample preparation, streamlined sequencing process on the GridION Q device, and finally the on-board no-click EPI2ME analysis. In this demo we will focus on the analysis and interpretation of the results. Biography Tim Walker works in the Applied Industrial Markets team at Oxford Nanopore Technologies where he has responsibility for ensuring industry partners achieve success with the technology through high-quality support, training, and consultancy. Tim has been with the company for nearly four years, and previously he worked for a major pharmaceutical company using next-generation sequencing for target discovery. Tim is passionate about helping to drive the adoption of nanopore sequencing for novel applications in the biopharma industry. Dr. Matt Parker is Director, Clinical Bioinformatics Software at Oxford Nanopore Technologies and sits in the Customer Workflows (EPI2ME) team. The Customer Workflows team produce bioinformatics analysis workflows and platforms (EPI2ME) for the analysis of Oxford Nanopore sequencing data. As a health care and professionals council registered clinical bioinformatician, Matt is interested in the potential of Oxford Nanopore sequencing to improve human health through better genomic diagnostics. Matt and his team are focused on developing medical device grade analysis workflows across infectious diseases, rare disease, and cancer that can be deployed on Oxford Nanopore devices and in the cloud to take Oxford Nanopore sequencing reads and derive meaningful clinical interpretations.